Salgueiro M, et al. - The published data on the use of long-acting injectable (LAI) formulation of second-generation antipsychotics (SGA) in first-episode psychosis (FEP) were reviewed to assess if LAI antipsychotics are a favorable option of treatment. Searching PubMed and Scopus databases, they identified and analyzed articles published between 1 January 2000 and 30 April 2018 and reported on the clinical trials on the use of LAI SGAs in patients with FEP. The FEP patients well accepted LAI SGAs treatment, and majority of them agreed to change from an oral to an injectable formulation. Treatment with LAI risperidone led to a good clinical response in 68% to 95% of FEP patients at the 12-month follow-up and remission of symptoms in 64% of patients for at least 24 months of follow-up. Outcomes thereby indicate LAI SGAs treatment to have a potential for conferring notable advantages over oral antipsychotics to FEP patients, especially to improve the adherence to medication and prevent the worsening of symptoms, the relapse, and rehospitalization associated with the discontinuation of treatment.